CD28 and cancer: In blood-born cancers, these fundamental differences in responses conveyed by CD28- and 4-1BB-incorporating CAR T cells might not play a significant role, because target cells are immediately accessible, ensuring a strong initial CAR T cell expansion independent of the co-stimulatory domain used and compensating for the slower and reduced effector molecule production by 4-1BB-incorporating second-generation CAR T cell designs.